SAFETY AND EFFICACY OF REGORAFENIB IN JAPANESE PATIENTS WITH METASTATIC COLORECTAL CANCER: A SUBGROUP ANALYSIS OF THE PHASE III CORRECT TRIAL

被引：0
|
作者：
Yamada, Y.
Yoshino, T. [1 ]
Komatsu, Y. [2 ]
Yamazaki, K. [3 ]
Tsuji, A. [4 ]
Ura, T. [5 ]
Grothey, A. [6 ]
Van Cutsem, E. [7 ]
Wagner, A. [8 ]
Ohtsu, A. [1 ]
机构：
[1] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[2] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan
[3] Shizuoka Canc Ctr, Shizuoka, Japan
[4] Kochi Hlth Sci Ctr, Kochi, Japan
[5] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[6] Mayo Clin Rochester, Rochester, MN USA
[7] Univ Hosp Gasthuisberg, Gasthuisberg, Belgium
[8] Bayer Pharma AG, Berlin, Germany
来源：
ANNALS OF ONCOLOGY | 2013年 / 24卷
关键词：
D O I：
10.1093/annonc/mdt459.81
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Analysis of tumor location: A retrospective trial for evaluating the safety and efficacy of regorafenib for patients with metastatic colorectal cancer: HGCSG1401
    Miyagishima, T.
    Yuki, S.
    Muranaka, T.
    Tsuji, Y.
    Ota, Y.
    Hatanaka, K.
    Okuda, H.
    Sasaki, T.
    Dazai, M.
    Konno, J.
    Nakamura, M.
    Ohta, T.
    Honda, T.
    Ishiguro, A.
    Muto, O.
    Kato, S.
    Sato, A.
    Abe, M.
    Sakata, Y.
    Komatsu, Y.
    ANNALS OF ONCOLOGY, 2017, 28
  • [22] Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL)
    Hisashi Hidaka
    Namiki Izumi
    Takeshi Aramaki
    Masafumi Ikeda
    Yoshitaka Inaba
    Kazuho Imanaka
    Takuji Okusaka
    Susumu Kanazawa
    Shuichi Kaneko
    Shinichi Kora
    Hiroya Saito
    Junji Furuse
    Osamu Matsui
    Tatsuya Yamashita
    Osamu Yokosuka
    Satoshi Morita
    Hitoshi Arioka
    Masatoshi Kudo
    Yasuaki Arai
    Medical Oncology, 2019, 36
  • [23] Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL)
    Hidaka, Hisashi
    Izumi, Namiki
    Aramaki, Takeshi
    Ikeda, Masafumi
    Inaba, Yoshitaka
    Imanaka, Kazuho
    Okusaka, Takuji
    Kanazawa, Susumu
    Kaneko, Shuichi
    Kora, Shinichi
    Saito, Hiroya
    Furuse, Junji
    Matsui, Osamu
    Yamashita, Tatsuya
    Yokosuka, Osamu
    Morita, Satoshi
    Arioka, Hitoshi
    Kudo, Masatoshi
    Arai, Yasuaki
    MEDICAL ONCOLOGY, 2019, 36 (06)
  • [24] Pharmacokinetics of regorafenib in the phase 3 CONCUR and CORRECT trials in patients with metastatic colorectal cancer (mCRC)
    Cleton, A.
    Sturm, I.
    Trnkova, Z. Jirakova
    Grevel, J.
    Fiala-Buskies, S.
    Lettieri, J.
    ANNALS OF ONCOLOGY, 2015, 26
  • [25] Efficacy and safety of regorafenib dose-escalation therapy for Japanese patients with refractory metastatic colorectal cancer (RECC study)
    Ishiyama, Shun
    Yamada, Takeshi
    Nakamura, Masato
    Enomoto, Masanobu
    Sugimoto, Kiichi
    Yokomizo, Hajime
    Kosugi, Chihiro
    Ohta, Ryo
    Ishimaru, Kei
    Sonoda, Hiromichi
    Ishibashi, Keiichiro
    Kuramochi, Hidekazu
    Yoshida, Yoichiro
    Ichikawa, Daisuke
    Hirata, Keiji
    Yoshida, Hiroshi
    Hashiguchi, Yojiro
    Ishida, Hideyuki
    Koda, Keiji
    Katsumata, Kenji
    Sakamoto, Kazuhiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (08) : 1300 - 1308
  • [26] Efficacy and safety of regorafenib dose-escalation therapy for Japanese patients with refractory metastatic colorectal cancer (RECC study)
    Shun Ishiyama
    Takeshi Yamada
    Masato Nakamura
    Masanobu Enomoto
    Kiichi Sugimoto
    Hajime Yokomizo
    Chihiro Kosugi
    Ryo Ohta
    Kei Ishimaru
    Hiromichi Sonoda
    Keiichiro Ishibashi
    Hidekazu Kuramochi
    Yoichiro Yoshida
    Daisuke Ichikawa
    Keiji Hirata
    Hiroshi Yoshida
    Yojiro Hashiguchi
    Hideyuki Ishida
    Keiji Koda
    Kenji Katsumata
    Kazuhiro Sakamoto
    International Journal of Clinical Oncology, 2022, 27 : 1300 - 1308
  • [27] Effects of regorafenib therapy on health-related quality of life in patients with metastatic colorectal cancer in the phase III CORRECT study
    Siena, S.
    Grothey, A.
    Sobrero, A.
    Falcone, A.
    Ychou, M.
    Lenz, H. J.
    Yoshino, T.
    Cihon, F.
    Pawar, V.
    Van Cutsem, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S482 - S482
  • [28] Effects of regorafenib therapy on health-related quality of life in patients with metastatic colorectal cancer in the phase III CORRECT study
    Stein, A.
    Siena, S.
    Grothey, A.
    Sobrero, A.
    Falcone, A.
    Ychou, M.
    Lenz, H. J.
    Yoshino, T.
    Cihon, F.
    Pawar, V.
    van Cutsem, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 40 - 40
  • [29] Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice
    Calcagno, Fabien
    Lenoble, Sabrina
    Lakkis, Zaher
    Nguyen, Thierry
    Limat, Samuel
    Borg, Christophe
    Jary, Marine
    Kim, Stefano
    Nerich, Virginie
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2016, 10 : 59 - 66
  • [30] Analysis of single-nucleotide polymorphisms (SNPs) in the phase 3 CORRECT trial of regorafenib vs placebo in patients with metastatic colorectal cancer (mCRC)
    Lambrechts, D.
    Koechert, K.
    Schulz, A.
    Vonk, R.
    Rutstein, M.
    Kobina, S.
    Grothey, A.
    Van Cutsem, E.
    Teufel, M.
    ANNALS OF ONCOLOGY, 2016, 27 : 102 - 102
12345